Admedus (ASX:AHZ) has made strong progress with its lead regenerative tissue product CardioCel® receiving initial orders in Hong Kong and expanding its footprint in France and Italy.
The company has now been granted an ASX trading halt in relation to a capital raising.
The halt will last until the earlier of the announcement being made or the start of trade on 18th March 2015.
CardioCel® is now used in over 60 centres globally with 28 in Europe and a further 28 centres in the U.S.
Over 1,200 patients have benefited from CardioCel® as part of their cardiovascular repair surgery.
It is also on track for its strongest sales quarter.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.